Higher resilience in radical cystectomy patients is associated with improved health related quality of life post-operatively [0.03%]
较高的弹性能改善膀胱全切术患者的术后相关生活质量
Lauren N Kennedy,Caleb S Miller,Danica N May et al.
Lauren N Kennedy et al.
Background: Radical cystectomy (RC) with urinary diversion (UD) is associated with substantial morbidity. Enhanced recovery after surgery protocols, increased robotic usage, and improvements in urinary diversion have been...
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates [0.03%]
肌层浸润性膀胱癌系统治疗进展：从最初到最新的更新系统综述
Takafumi Yanagisawa,Akihiro Matsukawa,Jeremy Yuen-Chun Teoh et al.
Takafumi Yanagisawa et al.
Context: Several phase III randomized controlled trials (RCTs) have shown the importance of perioperative systemic therapy, especially for the efficacy of immune checkpoint inhibitors (ICIs) in both neoadjuvant and adjuva...
Hongda Zhao,Vincy Wing Sze Ho,Kang Liu et al.
Hongda Zhao et al.
Background: Bladder cancer (BC), one of the most prevalent and aggressive urological malignancies, poses significant challenges in diagnosis, treatment, and recurrence management. Patient-derived organoid provides new dir...
Piyush K Agarwal,Cora N Sternberg
Piyush K Agarwal
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma [0.03%]
局部晚期或转移性尿路上皮癌在维持治疗使用avelumab或pembrolizumab之后再次使用铂类化疗或enfortumab vedotin治疗
Nobutaka Nishimura,Makito Miyake,Norimi Takamatsu et al.
Nobutaka Nishimura et al.
Background: In current clinical practice, the use of switch maintenance avelumab is recommended for patients with locally advanced and metastatic urothelial carcinoma who experience favorable responses to first-line chemo...
Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette-Guérin therapy in patients with non-muscle invasive bladder cancer [0.03%]
血清代谢组学分析识别出非肌层浸润性膀胱癌患者在卡介苗治疗后肿瘤复发的预测血清生物标志物
Makito Miyake,Kota Iida,Nobutaka Nishimura et al.
Makito Miyake et al.
Background: Metabolomic research and metabolomics-based biomarkers predicting treatment outcomes in bladder cancer remain limited. Objective: ...
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes [0.03%]
局部晚期或淋巴结阳性尿路上皮癌患者的系统诱导治疗：评估治疗结果
Vera C Rutten,Jan-Jaap Mellema,Tahlita Cm Zuiverloon et al.
Vera C Rutten et al.
Background: The presence of lymph node metastases in patients with urothelial carcinoma (UC) plays a pivotal role in disease management and prognosis. Patients with locally advanced irresectable or clinically node-positiv...
Repeat TURBT in large volume high-grade non-invasive bladder cancer [0.03%]
大体积高级别非肌层浸润性膀胱癌的重复TURBT治疗
Adri M Durant,Mimi Nguyen,Mouneeb M Choudry et al.
Adri M Durant et al.
Background: The American Urological Association (AUA)/Society of Urology Oncology (SUO) guidelines recommend a repeat transurethral resection of bladder tumor (TURBT) for high-risk, non-invasive (HR Ta) nonmuscle invasive...
Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies [0.03%]
实现膀胱癌治疗中的健康公平性：通过协作研究和基于证据的策略解决差异问题
Yelba Castellon-Lopez,Patricia A Thompson
Yelba Castellon-Lopez
The United States has seen a decrease in the incidence of bladder cancer and a decline in mortality rates over the past 20 years. However, not all groups have benefited equally from this trend. The American Association of Community Cancer C...